SynthesisActa paediatrica (Oslo, Norway : 1992)2025
Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines.
Synthesis in Acta paediatrica (Oslo, Norway : 1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics.World journal of clinical pediatrics · 2026Review
- Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this review is to systematically summarise the evidence on the effectiveness of riboflavin (vitamin B2) or supplements containing riboflavin in preventing paediatric migraines.
methodsThis systematic review followed the Joanna Briggs Institute methodology and is reported to adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched multiple electronic databases on 25 October 2023 to identify potentially relevant studies. Studies were screened, critically appraised and data extracted by two reviewers. Data underwent a narrative synthesis using vote counting based on direction of effect and was presented using harvest plots.
resultsSeventeen studies of varying quality were included in the review. Riboflavin or its combination with other natural ingredients was significantly effective in reducing migraine frequency (7/10 comparisons), migraine days (3/4 studies) and use of analgesics (3/4 studies). Mixed findings were found on headache duration in hours (3/5 studies), pain intensity (4/6 studies) and disability (3/5 studies). No negative outcomes and few side effects were reported (five studies).
conclusionOur findings suggest that using riboflavin at different dosages and treatment lengths offers a promising alternative to common medications for paediatric migraine prevention. Future research should explore mechanisms of action, optimal dosing and treatment duration using robust evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.